Brain, Vol. 116, No. 5, 1077-1094, 1993
© 1993 Guarantors of Brain
research-article |
Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis
1Departments of Clinical Neurology, National Hospital for Neurology and Neurosurgery London, UK 2Departments of Diagnostic Radiology Amsterdam, The Netherlands 3Departments of Epidemiology and Biostatistics, Free University Hospital Amsterdam, The Netherlands
Correspondence to:
Correspondence to Dr D Miller, University Department of Clinical Neurology, National Hospital for Neurology and Neurosurgery, London WC1N 3BG, UK
There is now widespread agreement that serial brain MRI is useful in monitoring treatments designed to modify the course of multiple sclerosis. It has been less clear whether gadolinium enhancement is needed. We therefore compared the relative sensitivity of long repetition time (TR) spin echo (SE) and gadolinium enhanced short TR SE sequences in detecting active lesions. A blind analysis of the two sequences was performed in 26 untreated patients with early relapsing-remitting (19) or secondary progressive (seven) multiple sclerosis who underwent monthly MRI on four occasions (one baseline and three follow-up). Active lesions were defined as either new or enlarged lesions on long TR SE, or new or persistent enhancing lesions on short TR SE.
In one patient there were 144 active lesions, all of which were seen with enhancement on short TR SE, but only 17 were seen on long TR SE. Amongst the remaining 25 cases, a total of 106 active lesions were seen: 68 (64%) were seen only with enhancement on short TR SE, 16 (15%) were seen only on long TR SE, while 22 (21%) were active on both sequences.
We conclude that gadolinium enhancement markedly increases the sensitivity of monthly brain MRI in monitoring the treatment of relapsing-remitting or secondary progressive multiple sclerosis. With this frequency of scanning, a post contrast short TR SE sequence is the most sensitive method for detecting active lesions. The smaller yet still substantial incidence of active lesions seen only on the long TR SE sequence suggests that it should also be obtained.
Received February 15, 1993. Revised June 10, 1993. Accepted June 15, 1993.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. P. Sormani, M. Rovaris, G. Comi, and M. Filippi A reassessment of the plateauing relationship between T2 lesion load and disability in MS Neurology, November 10, 2009; 73(19): 1538 - 1542. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L Bonzano, L Roccatagliata, G. Mancardi, and M. Sormani Gadolinium-enhancing or active T2 magnetic resonance imaging lesions in multiple sclerosis clinical trials? Multiple Sclerosis, September 1, 2009; 15(9): 1043 - 1047. [Abstract] [PDF]
|
|
|
|
|
|
E Fainardi, M Castellazzi, C Tamborino, A Trentini, M. Manfrinato, E Baldi, M. Tola, F Dallocchio, E Granieri, and T Bellini Potential relevance of cerebrospinal fluid and serum levels and intrathecal synthesis of active matrix metalloproteinase-2 (MMP-2) as markers of disease remission in patients with multiple sclerosis Multiple Sclerosis, May 1, 2009; 15(5): 547 - 554. [Abstract] [PDF]
|
|
|
|
 |
|
 J. A. Lincoln, D. Cadavid, J. Pollard, J. McLeod, J. Prineas, P. Dowling, and S. D. Cook We Should Use Magnetic Resonance Imaging to Classify and Monitor the Course of Multiple Sclerosis Arch Neurol, March 1, 2009; 66(3): 412 - 414. [Full Text] [PDF]
|
|
|
|
|
|
I. van den Elskamp, J Lembcke, V Dattola, K Beckmann, C Pohl, W Hong, R Sandbrink, K Wagner, D. Knol, B Uitdehaag, et al. Persistent T1 hypointensity as an MRI marker for treatment efficacy in multiple sclerosis Multiple Sclerosis, July 1, 2008; 14(6): 764 - 769. [Abstract] [PDF]
|
|
|
|
|
|
D Bar-Zohar, F Agosta, D Goldstaub, and M Filippi Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives Multiple Sclerosis, July 1, 2008; 14(6): 719 - 727. [Abstract] [PDF]
|
|
|
|
|
|
E. Fainardi, R. Rizzo, L. Melchiorri, M. Stignani, M. Castellazzi, C. Tamborino, E. Paolino, M. Tola, E. Granieri, and O. Baricordi CSF levels of soluble HLA-G and Fas molecules are inversely associated to MRI evidence of disease activity in patients with relapsing--remitting multiple sclerosis Multiple Sclerosis, May 1, 2008; 14(4): 446 - 454. [Abstract] [PDF]
|
|
|
|
 |
|
 Y. Duan, P.G. Hildenbrand, M.P. Sampat, D.F. Tate, I. Csapo, B. Moraal, R. Bakshi, F. Barkhof, D.S. Meier, and C.R.G. Guttmann Segmentation of Subtraction Images for the Measurement of Lesion Change in Multiple Sclerosis AJNR Am. J. Neuroradiol., February 1, 2008; 29(2): 340 - 346. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E Fainardi, M Castellazzi, T Bellini, M C Manfrinato, E Baldi, I Casetta, E Paolino, E Granieri, and F Dallocchio Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis Multiple Sclerosis, June 1, 2006; 12(3): 294 - 301. [Abstract] [PDF]
|
|
|
|
|
|
S Gupta, J M Solomon, T A Tasciyan, M M Cao, R D Stone, J L Ostuni, J M Ohayon, P A Muraro, J A Frank, N D Richert, et al. Interferon-beta-1b effects on re-enhancing lesions in patients with multiple sclerosis Multiple Sclerosis, December 1, 2005; 11(6): 658 - 668. [Abstract] [PDF]
|
|
|
|
|
|
C J da Silva, A J da Rocha, M F Mendes, A C. Maia Jr, F T Braga, and C P Tilbery Trigeminal involvement in multiple sclerosis: magnetic resonance imaging findings with clinical correlation in a series of patients Multiple Sclerosis, June 1, 2005; 11(3): 282 - 285. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Rovaris, F. Agosta, M. P. Sormani, M. Inglese, V. Martinelli, G. Comi, and M. Filippi Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study Brain, October 1, 2003; 126(10): 2323 - 2332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. O'Sullivan, P. M. Rich, T. R. Barrick, C. A. Clark, and H. S. Markus Frequency of Subclinical Lacunar Infarcts in Ischemic Leukoaraiosis and Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy AJNR Am. J. Neuroradiol., August 1, 2003; 24(7): 1348 - 1354. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Bagnato, N. Jeffries, N. D. Richert, R. D. Stone, J. M. Ohayon, H. F. McFarland, and J. A. Frank Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years Brain, August 1, 2003; 126(8): 1782 - 1789. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rovaris, M. Bozzali, G. Iannucci, A. Ghezzi, D. Caputo, E. Montanari, A. Bertolotto, R. Bergamaschi, R. Capra, G. L. Mancardi, et al. Assessment of Normal-Appearing White and Gray Matter in Patients With Primary Progressive Multiple Sclerosis: A Diffusion-Tensor Magnetic Resonance Imaging Study Arch Neurol, September 1, 2002; 59(9): 1406 - 1412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M P Sormani, P Bruzzi, M Rovaris, F Barkhof, G Comi, D H Miller, G R Cutter, and M Filippi Modelling new enhancing MRI lesion counts in multiple sclerosis Multiple Sclerosis, October 1, 2001; 7(5): 298 - 304. [Abstract] [PDF]
|
|
|
|
 |
|
 M P Sormani, D H Miller, G Comi, F Barkhof, M Rovaris, P Bruzzi, and M Filippi Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets J. Neurol. Neurosurg. Psychiatry, April 1, 2001; 70(4): 494 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Cercignani, M Bozzali, G Iannucci, G Comi, and M Filippi Magnetisation transfer ratio and mean diffusivity of normal appearing white and grey matter from patients with multiple sclerosis J. Neurol. Neurosurg. Psychiatry, March 1, 2001; 70(3): 311 - 317. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Koziol, S. Wagner, D. F. Sobel, L. S. Slivka, J. S. Romine, J. C. Sipe, and H.-P. Adams Predictive Value of Lesions for Relapses in Relapsing-remitting Multiple Sclerosis AJNR Am. J. Neuroradiol., February 1, 2001; 22(2): 284 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Filippi, M. Inglese, M. Rovaris, M. P. Sormani, M. A. Horsfield, G. Iannucci, B. Colombo, and G. Comi Magnetization transfer imaging to monitor the evolution of MS: A 1-year follow-up study Neurology, October 10, 2000; 55(7): 940 - 946. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. B. Pike, N. De Stefano, S. Narayanan, K. J. Worsley, D. Pelletier, G. S. Francis, J. P. Antel, and D. L. Arnold Multiple Sclerosis: Magnetization Transfer MR Imaging of White Matter before Lesion Appearance on T2-weighted Images Radiology, June 1, 2000; 215(3): 824 - 830. [Abstract] [Full Text]
|
|
|
|
|
|
I L Tan, G J L. Nijeholt, C H Polman, H J Ader, F Barkhof, and the 95 Line 146/147 Study Group Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials Multiple Sclerosis, April 1, 2000; 6(2): 99 - 104. [Abstract] [PDF]
|
|
|
|
|
|
Y. Ge, R. I. Grossman, J. K. Udupa, J. Fulton, C. S. Constantinescu, F. Gonzales-Scarano, J. S. Babb, L. J. Mannon, D. L. Kolson, and J. A. Cohen Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: Quantitative MR assessment Neurology, February 22, 2000; 54(4): 813 - 817. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F Bagnato, A Tancredi, N Richert, C Gasperini, S Bastianello, C Bash, H McFarland, C Pozzilli, and J A Frank Contrast-enhanced magnetic resonance activity in relapsing remitting multiple sclerosis patients: a short term natural history study Multiple Sclerosis, February 1, 2000; 6(1): 43 - 49. [Abstract] [PDF]
|
|
|
|
|
|
M Rovaris, B Viti, G Ciboddo, S Gerevini, R Capra, G Iannucci, G Comi, and M Filippi Brain involvement in systemic immune mediated diseases: magnetic resonance and magnetisation transfer imaging study J. Neurol. Neurosurg. Psychiatry, February 1, 2000; 68(2): 170 - 177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Zhao, R. A. Koopmans, D. K. B. Li, L. Bedell, and D. W. Paty Effect of interferon {beta}-1b in MS: Assessment of annual accumulation of PD/T2 activity on MRI Neurology, January 11, 2000; 54(1): 200 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R P Kinkel, J H Simon, and B Baron Bimonthly cranial MRI activity following an isolated monosymptomatic demyelinating syndrome: potential outcome measures for future multiple sclerosis `prevention' trials Multiple Sclerosis, October 1, 1999; 5(5): 307 - 312. [Abstract] [PDF]
|
|
|
|
|
|
P. A. Brex, J. I. O'Riordan, K. A. Miszkiel, I. F. Moseley, A. J. Thompson, G. T. Plant, and D. H. Miller Multisequence MRI in clinically isolated syndromes and the early development of MS Neurology, October 1, 1999; 53(6): 1184 - 1184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Fazekas, F. Barkhof, M. Filippi, R. I. Grossman, D. K. B. Li, W. I. McDonald, H. F. McFarland, D. W. Paty, J. H. Simon, J. S. Wolinsky, et al. The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis Neurology, August 1, 1999; 53(3): 448 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Wolinsky The mechanisms of lesion genesis in multiple sclerosis? Brain, July 1, 1999; 122(7): 1211 - 1212. [Full Text] [PDF]
|
|
|
|
|
|
M. A. Lee, S. Smith, J. Palace, S. Narayanan, N. Silver, L. Minicucci, M. Filippi, D. H. Miller, D. L. Arnold, and P. M. Matthews Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis? Brain, July 1, 1999; 122(7): 1261 - 1270. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. K. Jordan, H. I. McFarland, B. K. Lewis, N. Tresser, M. A. Gates, M. Johnson, M. Lenardo, L. A. Matis, H. F. McFarland, and J. A. Frank Serial MR Imaging of Experimental Autoimmune Encephalomyelitis Induced by Human White Matter or by Chimeric Myelin-Basic and Proteolipid Protein in the Common Marmoset AJNR Am. J. Neuroradiol., June 1, 1999; 20(6): 965 - 976. [Abstract] [Full Text]
|
|
|
|
|
|
G. Pike, de Stefano, Narayanan, G. Francis, J. Antel, and D. Arnold Combined Magnetization Transfer and Proton Spectroscopic Imaging in the Assessment of Pathologic Brain Lesions in Multiple AJNR Am. J. Neuroradiol., May 1, 1999; 20(5): 829 - 837. [Abstract] [Full Text]
|
|
|
|
|
|
M P Sormani, P D Molyneux, C Gasperini, F Barkhof, T A Yousry, D H Miller, and M Filippi Statistical power of MRI monitored trials in multiple sclerosis: new data and comparison with previous results J. Neurol. Neurosurg. Psychiatry, April 1, 1999; 66(4): 465 - 469. [Abstract] [Full Text]
|
|
|
|
|
|
D. Kidd, F. Barkhof, R. McConnell, P. R. Algra, I. V. Allen, and T. Revesz Cortical lesions in multiple sclerosis Brain, January 1, 1999; 122(1): 17 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Filippi, T. A Yousry, M. A Rocca, C. Pereira, H. Alkadhi, and G. Comi The effect of cross-talk on MRI lesion numbers and volumes in multiple sclerosis using conventional and turbo spin-echo Multiple Sclerosis, December 1, 1998; 4(6): 471 - 474. [Abstract] [PDF]
|
|
|
|
|
|
J. A. Koziol, S. Wagner, and H.-P. Adams Assessing information in T2-weighted MRI scans from secondary progressive MS patients Neurology, July 1, 1998; 51(1): 228 - 233. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Filippi, F. Barkhof, S. Bressi, T. Yousry, and D. Miller Inter-rater variability in reporting enhancing lesions present on standard and triple dose gadolinium scans of patients with multiple sclerosis Multiple Sclerosis, August 1, 1997; 3(4): 226 - 230. [Abstract] [PDF]
|
|
|
|
|
|
C. Schiepers, P. Van Hecke, R. Vandenberghe, S. Van Oostende, P. Dupont, P. Demaerel, G. Bormans, and H. Carton Positron emission tomography, magnetic resonance imaging and proton NMR spectroscopy of white matter in multiple sclerosis Multiple Sclerosis, February 1, 1997; 3(1): 8 - 17. [Abstract] [PDF]
|
|
|
|
|
|
L Truyen, F Barkhof, M Tas, M. Van Walderveen, S. Frequin, O. Hommes, J. Nauta, C. Polman, and J Valk Specific power calculations for magnetic resonance imaging (MRI) in monitoring active relapsing-remitting multiple sclerosis (MS): implications for phase II therapeutic trials Multiple Sclerosis, January 1, 1997; 2(6): 283 - 290. [Abstract] [PDF]
|
|
|
|
|
|
D. Miller Guidelines for MRI monitoring of the treatment of multiple sclerosis: recommendations of the US Multiple Sclerosis Society's task force Multiple Sclerosis, June 1, 1996; 1(6): 335 - 338. [Abstract] [PDF]
|
|
|
|
|
|
B. vanOosten, M Lai, F Barkhof, D. Miller, I. Moseley, A. Thompson, S Hodgkinson, and C. Polman A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis Multiple Sclerosis, June 1, 1996; 1(6): 339 - 342. [Abstract] [PDF]
|
|
|
|
|
|
T. Moreau, A Coles, M Wing, J Thorpe, D Miller, I Moseley, J Issacs, G Hale, D Clayton, N Scolding, et al. CAMPATH-1H in multiple sclerosis Multiple Sclerosis, June 1, 1996; 1(6): 357 - 365. [Abstract] [PDF]
|
|
|
|
|
|
D. E Goodkin MS clinical trial design for the future Multiple Sclerosis, June 1, 1996; 1(6): 393 - 399. [Abstract] [PDF]
|
|